https://www.oncogen.org/ 1.0 daily https://www.oncogen.org/article-in-press 1.0 daily https://www.oncogen.org/current-issue 1.0 daily https://www.oncogen.org/past-issues 1.0 daily https://www.oncogen.org/editorial-board 1.0 daily https://www.oncogen.org/information/editor-guidelines 1.0 daily https://www.oncogen.org/information/author-guidelines 1.0 daily https://www.oncogen.org/information/reviewer-guidelines 1.0 daily https://www.oncogen.org/information/processing-charges 1.0 daily https://www.oncogen.org/information/publication-ethics 1.0 daily https://www.oncogen.org/information/faqs 1.0 daily https://www.oncogen.org/contact-us 1.0 daily https://www.oncogen.org/about 1.0 daily https://www.oncogen.org/online-payment 1.0 daily https://www.oncogen.org/past-issues/volume-7-issue-1-year-2024 0.8 daily https://www.oncogen.org/past-issues/volume-6-issue-2-year-2023 0.8 daily https://www.oncogen.org/past-issues/volume-6-issue-1-year-2023 0.8 daily https://www.oncogen.org/past-issues/volume-5-issue-1-year-2022 0.8 daily https://www.oncogen.org/past-issues/volume-4-issue-1-year-2021 0.8 daily https://www.oncogen.org/past-issues/volume-3-issue-1-year-2020 0.8 daily https://www.oncogen.org/past-issues/volume-2-issue-5-year-2019 0.8 daily https://www.oncogen.org/past-issues/volume-2-issue-4-year-2019 0.8 daily https://www.oncogen.org/past-issues/volume-2-issue-3-year-2019 0.8 daily https://www.oncogen.org/past-issues/volume-2-issue-2-year-2019 0.8 daily https://www.oncogen.org/past-issues/volume-2-issue-1-year-2019 0.8 daily https://www.oncogen.org/past-issues/volume-1-issue-1-year-2018 0.8 daily https://www.oncogen.org/editorial-board/qiang-wei 0.8 daily https://www.oncogen.org/editorial-board/rammurti-t-kamble 0.8 daily https://www.oncogen.org/editorial-board/rao-gollapudi 0.8 daily https://www.oncogen.org/editorial-board/ling-yin 0.8 daily https://www.oncogen.org/editorial-board/nidhi-sharma 0.8 daily https://www.oncogen.org/editorial-board/alain-l-fymat 0.8 daily https://www.oncogen.org/editorial-board/sachin-kumar-deshmukh 0.8 daily https://www.oncogen.org/editorial-board/keishiro-aoyagi 0.8 daily https://www.oncogen.org/editorial-board/dagmara-magdalena-poprawski 0.8 daily https://www.oncogen.org/editorial-board/piyush-vyas 0.8 daily https://www.oncogen.org/editorial-board/chung-yi-chen 0.8 daily https://www.oncogen.org/editorial-board/xiaoming-xie 0.8 daily https://www.oncogen.org/editorial-board/veerendra-koppolu 0.8 daily https://www.oncogen.org/editorial-board/liwu-fu 0.8 daily https://www.oncogen.org/editorial-board/gianluca-franceschini 0.8 daily https://www.oncogen.org/editorial-board/maria-loreto-yanez-sepulveda 0.8 daily https://www.oncogen.org/editorial-board/domenico-albano 0.8 daily https://www.oncogen.org/editorial-board/ana-cecilia-belzarena 0.8 daily https://www.oncogen.org/editorial-board/renato-cuocolo 0.8 daily https://www.oncogen.org/editorial-board/andrea-zivi 0.8 daily https://www.oncogen.org/editorial-board/dawei-li 0.8 daily https://www.oncogen.org/editorial-board/george-k-paraskevas 0.8 daily https://www.oncogen.org/editorial-board/maddalena-mallozzi 0.8 daily https://www.oncogen.org/editorial-board/qian-xiao 0.8 daily https://www.oncogen.org/editorial-board/abdelmonem-awad-hegazy 0.8 daily https://www.oncogen.org/editorial-board/selma-sakhri 0.8 daily https://www.oncogen.org/editorial-board/chandra-prakash-prasad 0.8 daily https://www.oncogen.org/editorial-board/irami-araujo-filho 0.8 daily https://www.oncogen.org/editorial-board/pankaj-srivastava 0.8 daily https://www.oncogen.org/editorial-board/omer-sager 0.8 daily https://www.oncogen.org/editorial-board/luisa-aguirre-buexm 0.8 daily https://www.oncogen.org/editorial-board/agrusa-antonino 0.8 daily https://www.oncogen.org/editorial-board/emmanuel-andres 0.8 daily https://www.oncogen.org/editorial-board/ramy-refaat-youssef-ghali 0.8 daily https://www.oncogen.org/editorial-board/liren-li 0.8 daily https://www.oncogen.org/articles/oncology-and-cancer-current-perspectives-and-emerging-frontiers.pdf 0.8 daily https://www.oncogen.org/full-text/oncology-and-cancer-current-perspectives-and-emerging-frontiers 0.8 daily https://www.oncogen.org/abstract/oncology-and-cancer-current-perspectives-and-emerging-frontiers 0.8 daily https://www.oncogen.org/articles/fatal-case-of-gestational-trophoblastic-tumour-following-a-molar-pregnancy-in-a-low-resource-setting-a-case-report.pdf 0.8 daily https://www.oncogen.org/full-text/fatal-case-of-gestational-trophoblastic-tumour-following-a-molar-pregnancy-in-a-low-resource-setting-a-case-report 0.8 daily https://www.oncogen.org/abstract/fatal-case-of-gestational-trophoblastic-tumour-following-a-molar-pregnancy-in-a-low-resource-setting-a-case-report 0.8 daily https://www.oncogen.org/articles/targeting-overexpressed-cyclin-dependent-kinase-1-cdk1-in-human-cancers-kamalachalcone-a-emerged-as-potential-inhibitor-of-cdk1-kinase-through-in-silico-docking-study.pdf 0.8 daily https://www.oncogen.org/full-text/targeting-overexpressed-cyclin-dependent-kinase-1-cdk1-in-human-cancers-kamalachalcone-a-emerged-as-potential-inhibitor-of-cdk1-kinase-through-in-silico-docking-study 0.8 daily https://www.oncogen.org/abstract/targeting-overexpressed-cyclin-dependent-kinase-1-cdk1-in-human-cancers-kamalachalcone-a-emerged-as-potential-inhibitor-of-cdk1-kinase-through-in-silico-docking-study 0.8 daily https://www.oncogen.org/articles/chronic-inflammation-and-its-role-in-colorectal-cancer-development.pdf 0.8 daily https://www.oncogen.org/full-text/chronic-inflammation-and-its-role-in-colorectal-cancer-development 0.8 daily https://www.oncogen.org/abstract/chronic-inflammation-and-its-role-in-colorectal-cancer-development 0.8 daily https://www.oncogen.org/articles/does-a-healthy-and-regular-diet-prevent-cancer-amazing-medical-benefits-of-red-beet-beta-vulgaris-as-an-antioxidant.pdf 0.8 daily https://www.oncogen.org/full-text/does-a-healthy-and-regular-diet-prevent-cancer-amazing-medical-benefits-of-red-beet-beta-vulgaris-as-an-antioxidant 0.8 daily https://www.oncogen.org/abstract/does-a-healthy-and-regular-diet-prevent-cancer-amazing-medical-benefits-of-red-beet-beta-vulgaris-as-an-antioxidant 0.8 daily https://www.oncogen.org/articles/conversion-of-human-hepatoma-cells-by-520d-5p-to-benign-or-normal-liver-tissues-via-a-stemness-mediated-process.pdf 0.8 daily https://www.oncogen.org/full-text/conversion-of-human-hepatoma-cells-by-520d-5p-to-benign-or-normal-liver-tissues-via-a-stemness-mediated-process 0.8 daily https://www.oncogen.org/abstract/conversion-of-human-hepatoma-cells-by-520d-5p-to-benign-or-normal-liver-tissues-via-a-stemness-mediated-process 0.8 daily https://www.oncogen.org/articles/clinical-presentation-and-risk-assessment-of-ovarian-tumors-in-baghdadian-women.pdf 0.8 daily https://www.oncogen.org/full-text/clinical-presentation-and-risk-assessment-of-ovarian-tumors-in-baghdadian-women 0.8 daily https://www.oncogen.org/abstract/clinical-presentation-and-risk-assessment-of-ovarian-tumors-in-baghdadian-women 0.8 daily https://www.oncogen.org/articles/a-preliminary-study-on-the-anticancer-properties-of-oxytocin-a-neuroendocrine-regimen-with-oxytocin-antitumor-pineal-indoles-and-cannabidiol-in-untreatable-advanced-cancer-patients-progressing-on-pineal-indoles-and-cannabidiol-alone.pdf 0.8 daily https://www.oncogen.org/full-text/a-preliminary-study-on-the-anticancer-properties-of-oxytocin-a-neuroendocrine-regimen-with-oxytocin-antitumor-pineal-indoles-and-cannabidiol-in-untreatable-advanced-cancer-patients-progressing-on-pineal-indoles-and-cannabidiol-alone 0.8 daily https://www.oncogen.org/abstract/a-preliminary-study-on-the-anticancer-properties-of-oxytocin-a-neuroendocrine-regimen-with-oxytocin-antitumor-pineal-indoles-and-cannabidiol-in-untreatable-advanced-cancer-patients-progressing-on-pineal-indoles-and-cannabidiol-alone 0.8 daily https://www.oncogen.org/articles/non-small-cell-lung-cancer-prognosis-based-in-a-cut-off-value-for-plasma-basic-fibroblast-growth-factor-expression.pdf 0.8 daily https://www.oncogen.org/full-text/non-small-cell-lung-cancer-prognosis-based-in-a-cut-off-value-for-plasma-basic-fibroblast-growth-factor-expression 0.8 daily https://www.oncogen.org/abstract/non-small-cell-lung-cancer-prognosis-based-in-a-cut-off-value-for-plasma-basic-fibroblast-growth-factor-expression 0.8 daily https://www.oncogen.org/articles/management-interventions-and-public-health-policies-prevention-control-and-palliative-care-in-oncology.pdf 0.8 daily https://www.oncogen.org/full-text/management-interventions-and-public-health-policies-prevention-control-and-palliative-care-in-oncology 0.8 daily https://www.oncogen.org/abstract/management-interventions-and-public-health-policies-prevention-control-and-palliative-care-in-oncology 0.8 daily https://www.oncogen.org/articles/crispr-cas9-based-editing-of-cdk4-p107-and-tgf-1-in-human-breast-and-lung-cancer-cells.pdf 0.8 daily https://www.oncogen.org/full-text/crispr-cas9-based-editing-of-cdk4-p107-and-tgf-1-in-human-breast-and-lung-cancer-cells 0.8 daily https://www.oncogen.org/abstract/crispr-cas9-based-editing-of-cdk4-p107-and-tgf-1-in-human-breast-and-lung-cancer-cells 0.8 daily https://www.oncogen.org/articles/palliative-systemic-treatment-of-advanced-merkel-cell-carcinoma-in-the-pre-immunotherapy-era-a-retrospective-single-center-analysis-of-patients-with-an-orphan-neuroendocrine-malignancy.pdf 0.8 daily https://www.oncogen.org/full-text/palliative-systemic-treatment-of-advanced-merkel-cell-carcinoma-in-the-pre-immunotherapy-era-a-retrospective-single-center-analysis-of-patients-with-an-orphan-neuroendocrine-malignancy 0.8 daily https://www.oncogen.org/abstract/palliative-systemic-treatment-of-advanced-merkel-cell-carcinoma-in-the-pre-immunotherapy-era-a-retrospective-single-center-analysis-of-patients-with-an-orphan-neuroendocrine-malignancy 0.8 daily https://www.oncogen.org/articles/the-suppression-of-prolactin-is-required-for-the-treatment-of-advanced-prostate-cancer.pdf 0.8 daily https://www.oncogen.org/full-text/the-suppression-of-prolactin-is-required-for-the-treatment-of-advanced-prostate-cancer 0.8 daily https://www.oncogen.org/abstract/the-suppression-of-prolactin-is-required-for-the-treatment-of-advanced-prostate-cancer 0.8 daily https://www.oncogen.org/articles/post-translational-modifications-ptms-from-a-cancer-perspective-an-overview.pdf 0.8 daily https://www.oncogen.org/full-text/post-translational-modifications-ptms-from-a-cancer-perspective-an-overview 0.8 daily https://www.oncogen.org/abstract/post-translational-modifications-ptms-from-a-cancer-perspective-an-overview 0.8 daily https://www.oncogen.org/articles/cognitive-impairment-secondary-to-treatment-of-cured-brain-metastases-of-triple-negative-breast-carcinoma.pdf 0.8 daily https://www.oncogen.org/full-text/cognitive-impairment-secondary-to-treatment-of-cured-brain-metastases-of-triple-negative-breast-carcinoma 0.8 daily https://www.oncogen.org/abstract/cognitive-impairment-secondary-to-treatment-of-cured-brain-metastases-of-triple-negative-breast-carcinoma 0.8 daily https://www.oncogen.org/articles/single-subject-studies-in-prostate-cancer-how-graphing-psa-test-results-and-testosterone-levels-using-process-behavior-and-celeration-charts-can-provide-insight-and-guide-clinical--2823.pdf 0.8 daily https://www.oncogen.org/full-text/single-subject-studies-in-prostate-cancer-how-graphing-psa-test-results-and-testosterone-levels-using-process-behavior-and-celeration-charts-can-provide-insight-and-guide-clinical-decisions 0.8 daily https://www.oncogen.org/abstract/single-subject-studies-in-prostate-cancer-how-graphing-psa-test-results-and-testosterone-levels-using-process-behavior-and-celeration-charts-can-provide-insight-and-guide-clinical-decisions 0.8 daily https://www.oncogen.org/articles/a-clinical-study-of-biomarkers-to-predict-the-efficacy-of-cancer-immunotherapy-with-subcutaneous-low-dose-il-2-or-with-immune-checkpoint-inhibitors-74901.pdf 0.8 daily https://www.oncogen.org/full-text/a-clinical-study-of-biomarkers-to-predict-the-efficacy-of-cancer-immunotherapy-with-subcutaneous-low-dose-il-2-or-with-immune-checkpoint-inhibitors 0.8 daily https://www.oncogen.org/abstract/a-clinical-study-of-biomarkers-to-predict-the-efficacy-of-cancer-immunotherapy-with-subcutaneous-low-dose-il-2-or-with-immune-checkpoint-inhibitors 0.8 daily https://www.oncogen.org/articles/tumor-infiltrating-lymphocytes-expression-in-stage-iiic-iv-of-high-grade-serous-ovarian-cancer-variation-with-neoadjuvant-chemotherapy-and-prognostic-value-98146.pdf 0.8 daily https://www.oncogen.org/full-text/tumor-infiltrating-lymphocytes-expression-in-stage-iiic-iv-of-high-grade-serous-ovarian-cancer-variation-with-neoadjuvant-chemotherapy-and-prognostic-value 0.8 daily https://www.oncogen.org/abstract/tumor-infiltrating-lymphocytes-expression-in-stage-iiic-iv-of-high-grade-serous-ovarian-cancer-variation-with-neoadjuvant-chemotherapy-and-prognostic-value 0.8 daily https://www.oncogen.org/articles/the-importance-of-attenuated-total-reflectance-fourier-transform-infrared-atr-ftir-and-raman-biospectroscopy-of-single-walled-carbon-nanotubes-swcnt-and-multi-walled-carbon-nanotub.pdf 0.8 daily https://www.oncogen.org/full-text/the-importance-of-attenuated-total-reflectance-fourier-transform-infrared-atr-ftir-and-raman-biospectroscopy-of-single-walled-carbon-nanotubes-swcnt-and-multi-walled-carbon-nanotubes-mwcnt-in-interpreting-infrared-and-raman-spectra-of-human-cancer-cells-tissues-and-tumors 0.8 daily https://www.oncogen.org/abstract/the-importance-of-attenuated-total-reflectance-fourier-transform-infrared-atr-ftir-and-raman-biospectroscopy-of-single-walled-carbon-nanotubes-swcnt-and-multi-walled-carbon-nanotubes-mwcnt-in-interpreting-infrared-and-raman-spectra-of-human-cancer-cells-tissues-and-tumors 0.8 daily https://www.oncogen.org/articles/triple-hormonal-blockade-adt3-a-patient-s-perspective-16415.pdf 0.8 daily https://www.oncogen.org/full-text/triple-hormonal-blockade-adt3-a-patient-s-perspective 0.8 daily https://www.oncogen.org/abstract/triple-hormonal-blockade-adt3-a-patient-s-perspective 0.8 daily https://www.oncogen.org/articles/removal-of-carcinogenic-arsenic-from-drinking-water-by-the-application-of-ion-exchange-resins-84024.pdf 0.8 daily https://www.oncogen.org/full-text/removal-of-carcinogenic-arsenic-from-drinking-water-by-the-application-of-ion-exchange-resins 0.8 daily https://www.oncogen.org/abstract/removal-of-carcinogenic-arsenic-from-drinking-water-by-the-application-of-ion-exchange-resins 0.8 daily https://www.oncogen.org/articles/breast-metachronous-carcinoma-and-sarcoma-in-a-young-patient-leading-to-the-diagnosis-of-li-fraumeni-syndrome-14568.pdf 0.8 daily https://www.oncogen.org/full-text/breast-metachronous-carcinoma-and-sarcoma-in-a-young-patient-leading-to-the-diagnosis-of-li-fraumeni-syndrome 0.8 daily https://www.oncogen.org/abstract/breast-metachronous-carcinoma-and-sarcoma-in-a-young-patient-leading-to-the-diagnosis-of-li-fraumeni-syndrome 0.8 daily https://www.oncogen.org/articles/hearing-loss-tinnitus-and-pineal-germinoma-parinaud-dorsal-midbrain-syndrome-revisited-11635.pdf 0.8 daily https://www.oncogen.org/full-text/hearing-loss-tinnitus-and-pineal-germinoma-parinaud-dorsal-midbrain-syndrome-revisited 0.8 daily https://www.oncogen.org/abstract/hearing-loss-tinnitus-and-pineal-germinoma-parinaud-dorsal-midbrain-syndrome-revisited 0.8 daily https://www.oncogen.org/articles/chromatographic-fractionation-of-an-ethanolic-extract-of-peels-from-ipomoea-batatas-lam-for-improved-anticancer-activity-60223.pdf 0.8 daily https://www.oncogen.org/full-text/chromatographic-fractionation-of-an-ethanolic-extract-of-peels-from-ipomoea-batatas-lam-for-improved-anticancer-activity 0.8 daily https://www.oncogen.org/abstract/chromatographic-fractionation-of-an-ethanolic-extract-of-peels-from-ipomoea-batatas-lam-for-improved-anticancer-activity 0.8 daily https://www.oncogen.org/articles/primary-renal-lymphoma-a-case-report-39587.pdf 0.8 daily https://www.oncogen.org/full-text/primary-renal-lymphoma-a-case-report 0.8 daily https://www.oncogen.org/abstract/primary-renal-lymphoma-a-case-report 0.8 daily https://www.oncogen.org/articles/navigating-prostate-cancer-a-map-of-the-territory-and-guidelines-for-leveling-the-playing-field-shared-by-patients-care-providers-clinical-researchers-and-advocates.pdf 0.8 daily https://www.oncogen.org/full-text/navigating-prostate-cancer-a-map-of-the-territory-and-guidelines-for-leveling-the-playing-field-shared-by-patients-care-providers-clinical-researchers-and-advocates 0.8 daily https://www.oncogen.org/abstract/navigating-prostate-cancer-a-map-of-the-territory-and-guidelines-for-leveling-the-playing-field-shared-by-patients-care-providers-clinical-researchers-and-advocates 0.8 daily https://www.oncogen.org/articles/dynamical-stability-analysis-of-tumor-growth-and-invasion-a-reaction-diffusion-model.pdf 0.8 daily https://www.oncogen.org/full-text/dynamical-stability-analysis-of-tumor-growth-and-invasion-a-reaction-diffusion-model 0.8 daily https://www.oncogen.org/abstract/dynamical-stability-analysis-of-tumor-growth-and-invasion-a-reaction-diffusion-model 0.8 daily